Certara Announces Fall 2025 Certainty Circuit in EMEA, APAC

RADNOR, PA. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced its event lineup for Fall 2025: Certainty APAC, Certainty EMEA, and Certainty Discovery. Designed for Certara customers and partners, the summits share global industry trends in drug discovery and development and latest modeling and biosimulation capabilities and technologies that help increase the success rate of bringing new therapies to patients.

Certainty APAC will come to Korea on Sept. 18, China on Sept. 23, and Japan on Sept. 25. The on-site events offer exclusive access to industry leaders and clinical researchers with opportunities to achieve better certainty in drug development through the presentations related to Model-informed Drug Development (MIDD), clinical pharmacology, QSP, PBPK, and more.​ Highlights include:

• The Role of Clinical Pharmacology in New Drug Development with HyunA Lee, PhD, Sr. Manager, Clinical Pharmacology, Samsung Bioepis (Korea)
• ​ AI-Driven Dynamic Adaptive Clinical Programming Paradigm with Yiding Qu, MSc Statistical Programming Senior Manager, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
• Utilization of PBPK for regulatory submission: DDI risk assessment of CYP induction potential of Samtasu with Masatoshi Masuda, PhD Manager, Biometrics Clinical Pharmacology Group, Otsuka Pharmaceutical (Japan)

Certainty EMEA will take place Oct. 1-2 in Barcelona, Spain and feature sessions on how AI, regulatory changes, and business realities will affect every stage of development from molecule to market. This year’s program will showcase the latest science, technologies, case studies, and the tangible value MIDD is delivering across the industry. Highlights include:

• Keynote Session: Accelerating Drug Development – A Vision for 2030 with Stefan Platz, Senior Vice President of Clinical Pharmacology and Safety Sciences within AstraZeneca’s BioPharmaceuticals R&D unit
• New Approach Methodologies in Action: Real-World Progress and Future Directions in Nonclinical Safety with Helen-Marie Dunmore, PhD, Senior Director, Toxicology, Certara Drug Development Solutions
• Driving Smart Decision from Discovery to the Clinic, a panel with Platz; Stefano Zamuner, Vice President and Head, Clinical Pharmacology Modelling & Simulation at GSK; and Dr. Andrea Manfrin, Deputy Director of Clinical Investigations and Trials, MHRA
• Failure to Launch: The Hidden cost of Poor Strategy with Fran Brown, PhD, Global Head, Certara Drug Development Solutions

Following its acquisition last year of Chemaxon, Certara will now host Certainty Discovery, “From small molecules to sequences: Prepare for a new discovery landscape,” which will take place Nov. 4-5 in Frankfurt, Germany. The event will consist of one day of scientific conference and one day of user meetings. The scientific conference features renowned industry speakers including Filip Miljković, Associate Principal AI Scientist, AstraZeneca; John Cumming, Expert Scientist and Group Leader in Medicinal Chemistry, Roche; and Thomas Fox, Boehringer Ingelheim Principal Scientist Computational Chemistry, all discussing the impact of new modalities on therapy discovery.